- Home
- SBFG vs CRDF Comparison
SBFG vs CRDF Comparison
Compare SBFG & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBFG
- CRDF
- Stock Information
- Founded
- SBFG 1983
- CRDF 1999
- Country
- SBFG United States
- CRDF United States
- Employees
- SBFG N/A
- CRDF N/A
- Industry
- SBFG Major Banks
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SBFG Finance
- CRDF Health Care
- Exchange
- SBFG Nasdaq
- CRDF Nasdaq
- Market Cap
- SBFG 125.3M
- CRDF 144.4M
- IPO Year
- SBFG N/A
- CRDF N/A
- Fundamental
- Price
- SBFG $18.44
- CRDF $2.24
- Analyst Decision
- SBFG
- CRDF Strong Buy
- Analyst Count
- SBFG 0
- CRDF 5
- Target Price
- SBFG N/A
- CRDF $11.10
- AVG Volume (30 Days)
- SBFG 16.7K
- CRDF 859.8K
- Earning Date
- SBFG 10-30-2025
- CRDF 11-06-2025
- Dividend Yield
- SBFG 3.04%
- CRDF N/A
- EPS Growth
- SBFG 2.59
- CRDF N/A
- EPS
- SBFG 1.83
- CRDF N/A
- Revenue
- SBFG $61,225,000.00
- CRDF $545,000.00
- Revenue This Year
- SBFG N/A
- CRDF N/A
- Revenue Next Year
- SBFG N/A
- CRDF N/A
- P/E Ratio
- SBFG $10.80
- CRDF N/A
- Revenue Growth
- SBFG 9.45
- CRDF N/A
- 52 Week Low
- SBFG $17.10
- CRDF $1.90
- 52 Week High
- SBFG $24.48
- CRDF $5.64
- Technical
- Relative Strength Index (RSI)
- SBFG 37.99
- CRDF 49.79
- Support Level
- SBFG $18.20
- CRDF $2.20
- Resistance Level
- SBFG $19.79
- CRDF $2.46
- Average True Range (ATR)
- SBFG 0.54
- CRDF 0.12
- MACD
- SBFG -0.02
- CRDF 0.04
- Stochastic Oscillator
- SBFG 9.89
- CRDF 52.08
About SBFG SB Financial Group Inc.
SB Financial Group Inc that provides a range of community banking services, including commercial and consumer lending, personal and business banking, treasury management and merchant services, personal wealth management and brokerage services, and other financial services to individuals, businesses, and municipalities. It operates in single segment which is Banking.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.